Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole

Ahmet Soysal
Division of Pediatric Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Marmara University, Istanbul, Turkey

Abstract: Posaconazole is a triazole antifungal agent that has broad-spectrum activity against many yeasts and filamentous fungi, including Candida species, Cryptococcus neoformans, Aspergillus species, and Zygomycetes. This drug has been approved for the prevention of invasive fungal infections in patients with neutropenia and for the treatment of invasive fungal infections in hematopoietic stem cell transplant recipients with graft-versus-host disease. Studies on the clinical efficacy, safety, tolerability, and cost-effectiveness of posaconazole therapy were performed using the oral suspension form of the drug. Pharmacokinetic studies have found that the oral suspension form of posaconazole has problematic bioavailability: its absorption is affected by concomitant medication and food. This article discusses the pharmacokinetic properties of the newly developed posaconazole delayed-release tablet formulation and reviews the efficacy, safety, and cost-effectiveness of both the oral suspension and the new tablet formulation. In conclusion, the posaconazole tablet formulation has better systemic bioavailability, thereby enabling once-daily administration and better absorption in the presence of concomitant medication and food. However, well-designed clinical studies are needed to evaluate the use of the tablet formulation in real-life settings.

Keywords: posaconazole delayed-release tablet, prophylaxis, invasive fungal infections

Introduction

Invasive fungal infections (IFIs) are a common cause of morbidity and mortality in immunocompromised patients. The incidence of IFIs in immunocompromised patients depends on the following factors: the age of patients; underlying diseases, such as hematologic malignancies, solid organ cancers, hematopoietic stem cell transplantation (HSCT), solid organ transplantation, AIDS, primary immunodeficiencies, and secondary immunodeficiencies; chemotherapy regimens; and systemic antifungal prophylaxis administration. The incidence of IFIs has ranged from 2%–49% in adult patients.¹ In pediatric age groups, the incidence of IFIs is approximately 10% or higher in populations of patients with acute myeloid leukemia (AML) or recurrent acute leukemia (RAL) and in patients who undergo allogeneic HSCT.² The incidence of IFIs in patients with acute lymphatic leukemia are more variable, depending on the protocol and the cumulative presence of risk factors. The incidence of IFIs is considerably lower (<5%) in patients with non-Hodgkin lymphoma and in patients who undergo autologous HSCT, and IFIs are sporadic in patients with pediatric solid tumors, brain tumors, and Hodgkin’s lymphoma.² Moreover, pediatric patients with primary immunodeficiencies have an increased incidence of superficial fungal...
infections and IFIs. Inborn errors of the phagocyte NADPH oxidase complex (chronic granulomatous disease), severe congenital neutropenia, and leukocyte adhesion deficiency type 1 confer a predisposition to invasive aspergillosis and candidiasis. More rarely, inborn errors of IFN-γ immunity predispose individuals to endemic mycoses. Inborn errors of IL-17 immunity have recently been demonstrated to predispose individuals to chronic mucocutaneous candidiasis, whereas inborn errors of CARD9 immunity predispose individuals to deep dermatophytosis and invasive candidiasis. Chronic mucocutaneous candidiasis, invasive candidiasis, invasive aspergillosis, deep dermatophytosis, pneumocystosis, and endemic mycoses have all been observed in patients with primary immunodeficiencies. The overall case-fatality rates of IFIs have ranged from 20%–70%, with the poorest outcomes in patients with disseminated disease, central nervous system involvement, or persistent neutropenia.

Both yeasts and molds cause serious IFIs in immunocompromised patients. *Candida* is the most common yeast pathogen, accounting for most invasive yeast infections. On the other hand, *Aspergillus* is the most common mold pathogen in immunocompromised patients. Other fungal pathogens, including *Trichosporon* spp., *Fusarium* spp., *Scedosporium* spp., and Zygomycetes have been described in immunocompromised patients. Cho and Choi reported a high rate of fungal infections in autopsy findings from patients who died after prolonged neutropenic fever between 1966 and 1975. More than half of these patients had *Candida* infections. These findings support the use of antifungal prophylaxis in immunocompromised patients. In a double-blinded, randomized, multicenter trial, Goodman et al demonstrated that fluconazole prophylaxis reduced the incidence of both systemic and superficial fungal infections in severely immunocompromised patients who underwent bone marrow transplantation.

In this review, we summarize the use of posaconazole, especially the delayed-release tablet formulation, for the prevention of IFIs in immunocompromised patients.

**Posaconazole**

Posaconazole is a recently developed second-generation azole antifungal drug. This drug is derived from itraconazole by replacing the chlorine substituents in the phenyl ring with fluorine and by hydroxylating the triazole side chain, which improves its potency and spectrum of activity. Posaconazole is designated chemically as 4-[4-[4-[[3(R,5R)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)-3-furanyl]methoxy]-1,2,4-triazol-1-ylmethyl]-3-furanyl]phenyl]-1-piperazinyl]phenyl]-2-[(1S,2S)-1-ethyl-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazol-3-one. The chemical formula for posaconazole is C_{57}H_{42}F_{12}N_{8}O_{4}, and its molecular weight is 700.8. Figure 1 shows the structural formula of posaconazole.

**Mechanisms of action**

Similar to all azole antifungal agents, posaconazole inhibits cytochrome P450 (CYP450)-dependent lanosterol 14 alpha-demethylase (CYP51), which is an enzyme required for ergosterol synthesis and a major sterol component in the cell membrane of fungal cells. The inhibition of ergosterol synthesis by posaconazole leads to a depletion of ergosterol. The shortage of ergosterol weakens the stability of the fungal cell membrane, the transport of nutrients, and the synthesis of chitin. Furthermore, the inhibition of ergosterol synthesis causes the accumulation of toxic methylated ergosterol precursors, which leads to damage of the fungal cell membrane and increased permeability and inhibition of fungal cell growth. The mechanisms of resistance to azole antifungals arises either from mutations in the ERG11 gene encoding the target enzyme CYP51 or from the overexpression of efflux pumps.

**Spectrum of activity**

Posaconazole is active against all fungi with ergosterol in their cytoplasmic membrane. This drug exhibits organism-dependent fungicidal activity. Posaconazole has fungistatic activity against most *Candida* spp. and fungicidal activity against *Aspergillus* spp. and Mucormycetes. In contrast to fluconazole, itraconazole, and voriconazole, the breakpoints of susceptibility/resistance to posaconazole have not yet been sufficiently established. However, the epidemiological cut-off (ECOFF) values have been described using European Committee on Susceptibility Testing (EUCAST) methodology. The ECOFF for itraconazole resistance in *A. fumigatus* is >2 mg/L. The ECOFFs for posaconazole and voriconazole resistance in *A. fumigatus* are >0.25 mg/L and >2 mg/L, respectively. The Clinical and
Laboratory Standards Institute breakpoint for itraconazole and voriconazole resistance in *A. fumigatus*, *A. flavus*, and *A. terreus* is >1 mg/L, and the breakpoint against *A. niger* and *A. versicolor* is >2 mg/L. In addition, the breakpoint for posaconazole resistance in *A. fumigatus*, *A. flavus*, and *A. terreus* is >0.5 mg/L. Moreover, the EUCAST minimum inhibitory concentration (MIC) breakpoints for posaconazole susceptibility and resistance in *C. albicans*, *C. tropicalis*, and *C. parapsilosis* are ≤0.06 mg/L and >0.06 mg/L, respectively. However, the clinical breakpoints have not been established yet for other species of *Candida*. A novel study investigated 1,717 clinical isolates from patients with IFIs at 72 laboratories in North America, Europe, Latin America, and the Asia-Pacific region as part of the 2012 SENTRY Antimicrobial Surveillance Program. In this study posaconazole resistance for *Candida* species were found to be vary from 0.4% in *C. parapsilosis* strains to 5.6% in *C. krusei* strains. Posaconazole has encouraging activity against Zygomycetes. Posaconazole and itraconazole are the only available azoles that demonstrate activity against most Zygomycetes. However, itraconazole was significantly less active than posaconazole against all Zygomycetes species. A comparative study found that posaconazole exhibited lower MICs against Zygomycetes isolates than voriconazole and itraconazole. However, the antifungal activity of posaconazole was lower than that of amphotericin B. Sun et al compared the in vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of Zygomycetes. They found that the MICs (means) of posaconazole were approximately 1.6-fold, 33-fold, and 47-fold lower than those of itraconazole, voriconazole, and fluconazole, respectively. However, amphotericin B had the lowest MICs against all Zygomycetes isolates. Zygomycetes species differ in their susceptibility to posaconazole: MICs have ranged from 0.25 to 8 µg/mL for *Rhizopus* species, from 0.125 to 8 µg/mL for *Mucor* species, from 0.03 to 0.25 µg/mL for *A. corymbifera*, and from 0.03 to 1 µg/mL for *Cunninghamella* spp. The activity of posaconazole against the clinical isolates of Zygomycetes was lower than that of amphotericin B but higher than that of voriconazole, fluconazole, and itraconazole. Therefore, posaconazole exhibits potent activity against a large spectrum of fungi.

Pharmacokinetics and metabolism

Since 2006, posaconazole has been approved for use in the United States as an oral suspension. The Food and Drug Administration (FDA) approved a new delayed-release tablet formulation of posaconazole in November 2013. Recently, in March 2014, the FDA approved an intravenous formulation of posaconazole. Posaconazole is extensively distributed throughout the body, with good extravascular tissue penetration (volume of distribution 5–25 L/kg). Posaconazole is highly protein-bound (>98%), predominantly to albumin. Posaconazole has been primarily found as the parent compound in plasma. This drug undergoes limited hepatic metabolism. Of the circulating metabolites of posaconazole, the majority are glucuronide conjugates formed via UDP-glucuronidation. Posaconazole does not have any major oxidative metabolites of the CYP450 system. The mean half-life of posaconazole is 35 hours (20–66 hours), and its total body clearance is 32 L/hour. The elimination of posaconazole occurs predominantly through fecal excretion (77%), with the major component eliminated as the parent drug (66%) and to a lesser extent via renal clearance (14%). The pharmacokinetics of posaconazole in patients with hepatic dysfunction have not been sufficiently evaluated; however, dose adjustments are currently not recommended in patients with hepatic impairment, but posaconazole must be used with caution in patients with hepatic dysfunction. Posaconazole use in patients with renal dysfunction has been evaluated in a limited number of studies. Courtney et al evaluated the pharmacokinetics and safety of posaconazole in healthy subjects and in patients with mild (creatinine clearance [CR] 50–80 mL/min), moderate (CR 20–49 mL/min), and severe chronic renal disease (CR <20 mL/min; receiving outpatient hemodialysis). They found no correlation between posaconazole pharmacokinetics and mild-to-moderate renal disease. In addition, they found that the difference in the pre-dialyzed and post-dialyzed posaconazole concentrations was approximately 3%, which suggests that posaconazole was not removed by hemodialysis. The results of this study indicate that dosage adjustments for patients with varying degrees of renal disease are not required and that the drug was not removed by hemodialysis. These data demonstrate that posaconazole can be administered without dose adjustments, and supplemental doses are not needed after hemodialysis. However, sufficient data on the pharmacokinetics of posaconazole are not available in children. Krishna et al investigated the pharmacokinetic parameters, adverse events, and treatment outcomes of posaconazole as salvage therapy for IFIs in children younger than 18 years of age. In this small study, the researchers found that posaconazole concentrations in plasma were similar for juvenile and adult patients, which suggests that the clinical outcomes would be similar in adults and children with refractory IFIs.
Posaconazole oral suspension

The oral suspension of posaconazole is a white powder that is insoluble in water. Posaconazole (Noxafil) oral suspension is a white, cherry-flavored immediate-release suspension that contains 40 mg of posaconazole per mL. The pharmacokinetic properties of posaconazole have been studied in healthy adult volunteers. Courtney et al investigated the pharmacokinetics, safety, and tolerability of posaconazole in 103 healthy adults using a rising single-dose or rising multiple-dose schedule. In this study, the subjects either received single doses of posaconazole oral tablets (50–1,200 mg), rising multiple-dose posaconazole oral tablets (50–400 mg), or placebo. They reported that in the rising single-dose study, the levels of posaconazole in plasma increased proportionally with doses of 50–800 mg, and saturation of absorption occurred above 800 mg. Additionally, dose proportionality was observed in the rising multiple-dose study. In both studies, the authors found that the volume of distribution of posaconazole was large (range: 343–1,341 L), and the terminal-phase half-life of posaconazole was long (range: 25–31 hours). In those studies, posaconazole was well tolerated at all dose levels, and the adverse events were not dose-dependent. Following the administration of single- and twice-daily rising doses, the level of posaconazole exposure increased in a dose-proportional manner. Krieter et al investigated the pharmacokinetics of posaconazole in eight healthy male subjects who received a single 399 mg oral dose of posaconazole after consuming a high-fat breakfast. They found that posaconazole was orally bioavailable, and the median maximum concentration in plasma was achieved by 10 hours following dosing. Thereafter, posaconazole was slowly eliminated, with a mean half-life of 20 hours. The steady-state concentrations of posaconazole were reached 7–10 days after the initiation of treatment. The consumption of food greatly affects posaconazole absorption similar to itraconazole. The absorption of the oral suspension is approximately three times higher when administered with a non-fat meal and approximately four times higher when administered with a high-fat meal. Therefore, to attain adequate plasma concentrations, recommendations suggest taking posaconazole with food or a nutritional supplement. The posaconazole oral suspension exhibits a greater degree of unpredictable bioavailability outside of ideal study conditions and in patients other than healthy adults. Intertemporal variability of approximately 68% has been observed in neutropenic stem cell transplant recipients. Several studies have investigated the relationship between gastric motility, drug absorption, and posaconazole plasma concentrations.

Diarrhea, mucositis, and graft-versus-host disease (GVHD) affect the absorption of posaconazole suspension. Moreover, many studies have demonstrated that gastric acid suppression therapy results in subtherapeutic posaconazole concentrations.

Posaconazole oral delayed-release tablet

The posaconazole delayed-release tablet is yellow, coated, and oblong, and it contains 100 mg of posaconazole. Each delayed-release tablet contains the following inactive ingredients: hypromellose acetate succinate, microcrystalline cellulose, hydroxypropyl cellulose, silicon dioxide, croscarmellose sodium, magnesium stearate, and Opadry® II Yellow (consisting of the following ingredients: polyvinyl alcohol partially hydrolyzed, macrogol/PEG 3350, titanium dioxide, talc, and iron oxide yellow). Posaconazole delayed-release tablets must be swallowed whole and cannot be divided, crushed, or chewed. The delayed-release tablet and oral suspension may not be used interchangeably due to differences in the dosing of each formulation. The first study to evaluate the pharmacokinetics of the delayed-release tablet formulation was a single-dose crossover study in 16 healthy adults under fasted and fed conditions. This study was aimed at assessing the safety and tolerability of the drug. In this study, the pharmacokinetics of 100 mg of posaconazole oral suspension, 100 mg of a posaconazole two-tablet formulation, and 100 mg of a posaconazole capsule formulation were assessed. Under fasted conditions, the posaconazole exposures (area under the curve [AUC]) for the first tablet and second capsule formulations against oral suspension formulation were similar (mean AUC from zero to infinity [AUC\textsubscript{\text{0–\infty}}]: 11,700/11,300 ng·h/mL versus 11,000 ng·h/mL) and were substantially higher than the exposure for the oral suspension (mean AUC\textsubscript{\text{0–\infty}}: 3,420 ng·h/mL). Moreover, in the fed subjects, the first tablets and second capsule against oral suspension form had similar mean AUC\textsubscript{\text{0–\infty}} values (11,900/12,400 ng·h/mL versus 12,300 ng·h/mL) and slightly higher mean AUC\textsubscript{\text{0–\infty}} values (8,750 ng·h/mL) than the oral suspension. The researchers demonstrated that the median times to the maximum concentration of the drug in plasma ranged from 4 to 5 hours (fasted conditions) and 6 to 8 hours (fed conditions), and the mean half-life values were similar for all the formulations under fed and fasted conditions (23.1–29.2 hours). Consistent with previous data on the posaconazole oral suspension, exposure for the oral suspension increased 2.5- to threefold when given with a high-fat meal. Conversely, the exposures for the tablets and capsule were not markedly affected by food. This study demonstrated...
that all formulations of posaconazole at 100 mg were safe and well tolerated, and the tablet and capsule formulations were not affected by food. These same researchers performed a second Phase I single-center, randomized, placebo-controlled trial to investigate rising single and multiple doses of posaconazole in healthy subjects of 18–65 years of age. The subjects received posaconazole oral tablets (100 mg) as 200 mg once daily (QD), 200 mg twice daily, or 400 mg QD.20 After the single or multiple oral dose administration of posaconazole tablets (200 and 400 mg), exposure increased in a dose-related manner, and peak posaconazole concentrations were achieved at a median T (max) of 4–5 hours. The mean half-life of the 200 and 400 mg posaconazole doses were similar (25 and 26 hours, respectively). The accumulation ratio for multiple doses over 8 days was approximately 3 for the 200 and 400 mg QD dosages and approximately 5 for the 200 mg twice-daily dosage. The posaconazole tablet formulation attained mean average concentration (C_{avg}) values >1,300 ng/mL at the lowest dose (200 mg QD), and these values were above the average concentration values that are associated with efficacy in patients with IFIs. This study concluded that the posaconazole oral tablet was safe and well tolerated and that the QD dosing regimens were appropriate for fungal infections; however, mild, transient elevations in liver function were reported in several patients.

Thereafter, a Phase Ib global (nine centers in four different countries), open-labeled, uncontrolled, dose-escalation, prospective pharmacokinetics and safety trial was conducted in adults with AML or myelodysplastic syndrome (MDS) who were undergoing remission-induction chemotherapy with prolonged neutropenia for at least 7 days.30 In this study, the patients were divided into two sequential dosing cohorts. The first cohort of 20 neutropenic patients received posaconazole tablets 200 mg QD, whereas the second dosing cohort of 34 patients received posaconazole tablets 300 mg QD. Both cohorts received posaconazole tablets twice daily on day 1; thereafter, posaconazole tablet dosing was QD anytime during the day. Posaconazole tablets were taken without regard to food intake for a maximum of 28 days. The primary aim of this study was to determine whether a posaconazole dosage could achieve a desired steady-state C_{avg} plasma concentration range of 500–2,500 ng/mL. The exposure target was reached (day 8) in 15 of 19 (79%) pharmacokinetic-evaluable patients who took 200 mg posaconazole QD and in 31 of 32 (97%) patients who took 300 mg posaconazole QD. Overall, 300 mg posaconazole QD achieved the desired exposure target. Therefore, the second part of this study predominantly focused on Phase III results and included neutropic patients with AML or MDS, and post-allogeneic HSCT patients. The subjects received (without regard to food) posaconazole 300 mg QD (after day 1, a twice-daily dose) for 28 days. The pharmacokinetic parameter of interest was the steady-state predicted average posaconazole concentration with lower and upper exposure target limits of ≥500 and <3,750 ng/mL. A total of 210 AML, MDS, or HSCT subjects received and tolerated posaconazole tablets 300 mg QD given as antifungal prophylaxis; 186 subjects were considered evaluable for pharmacokinetics. A strong correlation was found between the posaconazole trough concentration and observed C_{avg} values ($R^2$=0.92). Only 1/186 (<1%) pharmacokinetic-evaluable subjects did not achieve the lower exposure target; 7/186 (4%) subjects exceeded the upper exposure target. In this trial, a quartile analysis revealed no evidence of an increase in adverse event reporting with higher posaconazole exposure. This study revealed that posaconazole tablets 300 mg QD had an acceptable safety profile similar to that previously reported for posaconazole oral suspension, and the most commonly reported treatment-related adverse events were nausea (11%) and diarrhea (8%).31 The advantages of the newly developed posaconazole tablet form are not affected by gastric acid suppression treatment in contrast to oral posaconazole suspension, which was demonstrated by Kraft et al.32 They investigated the effects of concomitant medications that alter gastric pH levels (antacids, ranitidine, and esomeprazole) and gastric motility (metoclopramide) on the pharmacokinetics of the new posaconazole tablets. This trial was a prospective, open-labeled, five-way crossover study in 20 healthy volunteers. For each treatment period, a single 400-mg dose (four 100-mg tablets) of posaconazole was given alone or with 20 mL of antacid (2 g of aluminum hydroxide and 2 g of magnesium hydroxide), ranitidine (150 mg), esomeprazole (40 mg), or metoclopramide (15 mg). They reported that the mean $\text{AUC}_{0-\infty}$ values for the posaconazole tablet alone, posaconazole plus antacid, posaconazole plus ranitidine, posaconazole plus esomeprazole, and posaconazole plus metoclopramide were 42,406 (h·ng/mL), 42,468 (h·ng/mL), 39,287 (h·ng/mL), 41,574 (h·ng/mL), and 38,513 (h·ng/mL), respectively. Similarly, they found that the maximum concentration geometric mean ratios for posaconazole plus treatment compared with that for posaconazole alone were 1.06 for the antacid, 1.04 for ranitidine, 1.05 for esomeprazole, and 0.86 for metoclopramide. This study demonstrated that the pharmacokinetics of posaconazole tablets were similar when the drug was administered alone or with an antacid, ranitidine, esomeprazole, or metoclopramide.32
Adverse effects

The common treatment-related adverse reactions to oral posaconazole suspension include diarrhea, nausea, fever, vomiting, headache, coughing, and hypokalemia. Previous studies that investigated the pharmacokinetics and safety of the posaconazole tablet formulation revealed that the most commonly observed adverse effects were a mild increase in hepatic enzymes, diarrhea, headache, flatulence, and somnolence, which indicates that the treatment-related adverse effects of the posaconazole tablet form are similar to those of the posaconazole oral suspension.\textsuperscript{29–32}

Drug interactions

Posaconazole undergoes hepatic metabolism by UDP-glucuronidation, is a substrate for the membrane transporter P-glycoprotein, and is an inhibitor of the CYP3A4 enzyme; therefore, posaconazole has various drug–drug interactions.\textsuperscript{11,12,18} Rifabutin, phenytoin, efavirenz, cimetidine, esomeprazole, digoxin, fosamprenavir, metoclopramide, ritonavir, atazanavir, tacrolimus, cyclosporine, sirolimus, midazolam, simvastatin, and other drugs that are metabolized by CYP3A4 are well-known drugs that interact with posaconazole. In contrast to posaconazole suspension, posaconazole tablets do not have clinically significant drug–drug interactions with esomeprazole and metoclopramide, and no dosage adjustments are required.\textsuperscript{11,12,18}

Posaconazole (oral suspension) prophylaxis for IFIs

The prophylactic use of posaconazole oral suspension has been approved for invasive Aspergillus and Candida infections in patients 13 years of age and older who are at a high risk of developing these infections due to being severely immunocompromised, such as HSCT recipients with GVHD or patients with hematologic malignancies with prolonged neutropenia from chemotherapy. Moreover, posaconazole oral suspension has been approved for the treatment of oropharyngeal candidiasis similar to itraconazole and fluconazole.\textsuperscript{33}

One of the largest clinical trials to investigate the prophylactic use of posaconazole in patients with neutropenia resulting from chemotherapy for AML or MDS was performed by Cornely et al. In this randomized, multicenter study, patients (13 years of age or older) received prophylaxis with each cycle of chemotherapy until recovery from neutropenia and complete remission, the occurrence of an IFI, or up to 12 weeks. A total of 304 patients were randomly assigned to receive posaconazole, and 298 patients were randomly assigned to receive fluconazole (n=240) or itraconazole (n=58). Proven or probable IFIs were reported in seven patients (2%) in the posaconazole group, and in 25 patients (8%) in the fluconazole and itraconazole groups (P<0.001); therefore, these statistical criteria support the superiority of posaconazole. Moreover, significantly fewer patients in the posaconazole group had invasive aspergillosis (two or 1% versus 20 or 7%, P<0.001). Additionally, survival was significantly longer among the recipients of posaconazole than among the recipients of fluconazole or itraconazole (P=0.04). This study demonstrated that in patients who were undergoing chemotherapy for AML or MDS, posaconazole prevented IFIs more effectively than fluconazole or itraconazole and improved overall survival.\textsuperscript{34} In another large clinical study, Ulmann et al investigated posaconazole prophylaxis in an international, randomized, double-blinded trial of patients (13 years of age or older) with GVHD who were receiving immunosuppressive therapy. A total of 600 patients were enrolled. Of these patients, 301 received posaconazole and 299 received fluconazole. The incidences of IFIs were 5.3% in the posaconazole group and 9.0% in the fluconazole group (P=0.07). The incidence of proven or probable invasive aspergillosis was 2.3% in the posaconazole group versus 7.0% in the fluconazole group (P=0.006). Compared with the fluconazole group, fewer breakthrough IFIs were reported in the posaconazole group (2.4% versus 7.6%, P=0.004), particularly invasive aspergillosis (1.0% versus 5.9%, P=0.01). Moreover, the overall mortality was similar between the two groups; however, the number of deaths from IFIs was lower in the posaconazole group than in the fluconazole group (1% versus 4%; P=0.046). This study found that posaconazole was similar to fluconazole for prophylaxis against fungal infections among patients with GVHD. However, posaconazole was superior in preventing invasive aspergillosis and in reducing the rate of deaths related to fungal infections.\textsuperscript{35}

In addition to these large randomized studies, many studies have investigated the efficacy of posaconazole prophylaxis in immunocompromised patients. The findings from these observational studies and single-center experiences in real-life settings support the use of posaconazole prophylaxis beyond clinical studies (Table 1).

Posaconazole oral suspension has become the drug of choice for IFI prevention in AML or MDS patients with chemotherapy-induced neutropenia and in allogeneic HSCT recipients with GVHD. The Infectious Diseases Working Group of the German Society for Hematology and Oncology strongly recommends posaconazole prophylaxis in these patient populations as a standard of care with an A1 strength.\textsuperscript{36}
Table 1 Comparative studies in adult patients investigating posaconazole oral suspension prophylaxis against invasive fungal infections

<table>
<thead>
<tr>
<th>Author</th>
<th>Study design</th>
<th>Study population</th>
<th>Study population age range (years)</th>
<th>Underlying immunocompromised diseases</th>
<th>Posaconazole</th>
<th>Comparator drugs</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cornely et al</td>
<td>Randomized, multicenter</td>
<td>602</td>
<td>13–82</td>
<td>AML, MDS</td>
<td>n=304; 200 mg oral susp tid</td>
<td>n=240, FLC 400 mg oral susp qd; n=58, ITC 200 mg oral sol bid</td>
<td>IFl: 7 in Pos, 25 in FLC/ITC (P&lt;0.001); IA: 2 in Pos, 20 in FLC/ITC (P&lt;0.001); Mort: 49 in Pos, 67 in FLC/IT (P=0.048)</td>
</tr>
<tr>
<td>Ullmann et al</td>
<td>Randomized, double-blind</td>
<td>600</td>
<td>13–72</td>
<td>HSCT-GVHD</td>
<td>n=301; 200 mg oral susp tid</td>
<td>n=299; FLC 400 mg tb qd</td>
<td>IFl: 16 in Pos, 27 in FLC (P=0.07); IA: 7 in Pos, 21 in FLC (P=0.006); Mort: 76 in Pos, 84 in FLC (P=0.046)</td>
</tr>
<tr>
<td>Shen et al</td>
<td>Randomized, multicenter</td>
<td>252</td>
<td>?</td>
<td>AML, MDS</td>
<td>n=129</td>
<td>n=123 FLC</td>
<td>IFl: 11 in Pos, 26 in FLC (P=0.01)</td>
</tr>
<tr>
<td>Kung et al</td>
<td>Retrospective cohort, single-center</td>
<td>130</td>
<td>21–83</td>
<td>AML, MDS</td>
<td>n=65, 200 mg oral susp tid</td>
<td>n=65; FLC 400 mg oral qd</td>
<td>IFl: 6 in Pos, 17 in FLC (P=0.012); Mort: 23% in Pos, 25% in FLC (P=0.72)</td>
</tr>
<tr>
<td>Girmenia et al</td>
<td>Single-center</td>
<td>157</td>
<td>20–77</td>
<td>AML</td>
<td>n=99, 200 mg oral susp tid</td>
<td>n=58; ampB oral susp</td>
<td>IFl: 23 in Pos, 30 in ampB (P=0.0002); IA: 15 in Pos, 25 in ampB (P=0.0002); Mort: 52 in Pos, 29 in ampB (P=0.08)</td>
</tr>
<tr>
<td>Peterson et al</td>
<td>Retrospective cohort</td>
<td>200</td>
<td>18–77</td>
<td>AML, MDS, HSCT</td>
<td>n=100, 200 mg oral susp tid</td>
<td>n=100, none</td>
<td>IFl: 28 in Pos, 57 in none</td>
</tr>
<tr>
<td>Vehreschild et al</td>
<td>Prospective cohort</td>
<td>159</td>
<td>18–76</td>
<td>AML</td>
<td>n=77; 200 mg oral susp tid</td>
<td>n=82; topical polyene</td>
<td>IFl: 3 in Pos, 16 in polyene (P=0.003); IA: 2 in Pos, 11 in polyene (P=0.018)</td>
</tr>
<tr>
<td>Sánchez-Ortega et al</td>
<td>Observational, single-center</td>
<td>49</td>
<td>20–68</td>
<td>HSCT (AML-MDS, ALL)</td>
<td>n=33, 200 mg oral susp tid</td>
<td>n=16, ITC either oral or IV 200 mg bid</td>
<td>IFl: 0% in Pos, 12% in ITC (P=0.04)</td>
</tr>
<tr>
<td>Pagano et al</td>
<td>Multicenter, prospective</td>
<td>353</td>
<td>44–67</td>
<td>AML</td>
<td>n=260, 200 mg oral susp tid</td>
<td>n=93 ITC; 2.5 mg/kg oral susp bid</td>
<td>IFl: 18.9% in Pos, 38.7% in ITC (P&lt;0.01); Mort: 3.5% in Pos, 9.7% in ITC (P=0.02)</td>
</tr>
<tr>
<td>Wang et al</td>
<td>Single-center, retrospective</td>
<td>52</td>
<td>23–51</td>
<td>HSCT</td>
<td>n=12, 200 mg oral susp tid</td>
<td>n=40, FLC 100–400 mg/day oral tb qd</td>
<td>IFl: 1 in Pos, 17 in FLC (P=0.039)</td>
</tr>
<tr>
<td>Devanlay et al</td>
<td>Single-center, retrospective</td>
<td>91</td>
<td>23–80</td>
<td>AML</td>
<td>n=52; 200 mg oral susp tid</td>
<td>n=39; FLC 400 mg po qd</td>
<td>IFl: 8 in Pos, 9 in FLC (P=1.0)</td>
</tr>
<tr>
<td>Chaftari et al</td>
<td>Randomized, prospective</td>
<td>46</td>
<td>20–69</td>
<td>HSCT</td>
<td>n=21; 200 mg oral susp tid</td>
<td>n=19 ABLC 7.5 mg/kg IV weekly</td>
<td>IFl: 0 in Pos, 1 in ABLC (P=0.48)</td>
</tr>
</tbody>
</table>

**Abbreviations:** ABLC, amphotericin B lipid complex; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ampB, amphotericin B; FLC, fluconazole; GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; IA, invasive aspergillosis; IFl, invasive fungal infection; ITC, itraconazole; IV, intravenous; MDS, myelodysplastic syndrome; Mort, mortality; po, per oral; Pos, posaconazole; sol, suspension; tb, tablet; tid, three times a day; bid, twice a day; qd, every day.
Limited data are available on the prophylactic use of posaconazole oral suspension in immunocompromised children, especially under 13 years of age. Döring et al retrospectively analyzed antifungal prophylaxis with posaconazole versus fluconazole or itraconazole in a single-center nonrandomized survey of 93 pediatric patients with neutropenia. Overall, 31 of 93 patients received fluconazole 5 mg/kg/day, 32 patients received itraconazole 5 mg/kg twice daily, and 31 patients received posaconazole 4 mg/kg three times daily. Overall, two IFIs occurred in the fluconazole group, three IFIs occurred in the itraconazole group, and one IFI occurred in the posaconazole group. The blood analysis of liver and kidney parameters revealed a significant increase beyond the upper normal limit of alanine trasaminase (ALT) levels between the baseline and maximum values in all three groups. An increase in ALT levels that is 1.5 times greater from baseline and 2.5 times greater from the maximum value occurred in a total of 12 pediatric patients in the fluconazole group, eleven pediatric patients in the itraconazole group, and eight pediatric patients in the posaconazole group. An increase in aspartate aminotransferase (AST) levels that is 1.5 times greater from baseline and 2.5 times greater from the maximum value occurred in a total of seven pediatric patients in the fluconazole group, five pediatric patients in the itraconazole group, and six pediatric patients in the posaconazole group. This study demonstrated that posaconazole, fluconazole, and itraconazole are comparably effective in preventing IFIs in pediatric patients.37 In another study, Döring et al retrospectively assessed the safety, feasibility, and efficacy of prophylactic posaconazole in children who underwent allogeneic HSCT. Among 60 pediatric patients, 28 received posaconazole oral suspension 5 mg/kg twice daily, and 32 received posaconazole oral suspension 4 mg/kg three times daily. No IFIs were observed during treatment with posaconazole as antifungal prophylaxis, and five patients (8.3%) died of causes other than IFIs during the study period. Only minor side effects potentially related to posaconazole were recorded in five (8.3%) of the 60 patients, which included one patient with pruritus (1.7%), three patients with nausea (5%), and one patient with vomiting (1.7%). This study found that posaconazole is a well-tolerated, safe, and effective oral antifungal prophylaxis in pediatric patients who underwent high-dose chemotherapy and HSCT.38 Moreover, Döring et al compared itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic HSCT. Fifty consecutive pediatric patients received itraconazole (2×5 mg/kg 7 day), 50 received voriconazole (2×100 mg day for body weight <40 kg and 2×200 mg day for body weight >40 kg), and 50 received posaconazole (3×4 mg/kg day). No proven or probable IFIs were observed during the itraconazole, voriconazole, and posaconazole treatments. A total of five possible IFIs occurred: two in the itraconazole group (4%) and three in the voriconazole group (6%). Overall, nine of 150 (6%) pediatric patients died of causes other than IFIs during the observation period: five in the itraconazole group, two in the voriconazole group, and two in the posaconazole group. Adverse events potentially related to the antifungal prophylaxis were observed in six patients (12.0%) in the itraconazole group, seven (14.0%) patients in the voriconazole group, and four (8.0%) patients in the posaconazole group. The findings of this study support previous findings that itraconazole, voriconazole, and posaconazole had a comparable efficacy as antifungal prophylaxis in pediatric patients after allogeneic HSCT.39 Yunus et al analyzed the safety and efficacy of azole-based, mold-active antifungal prophylaxis in children with AML and RALs. In this study, the patients with AML and RALs who were ≥13 years of age received 200 mg of posaconazole three times daily and patients 2–12 years of age received 200 mg of voriconazole two times daily from the completion of chemotherapy until hematopoietic recovery. The researchers enrolled a total of 40 patients during the 5-year observation period, of whom 36 received a total of 149 courses of chemotherapy. Azole prophylaxis was given in 87.2% of the episodes. No proven or probable IFIs were reported during the study.40 These studies demonstrated that posaconazole prophylaxis in children in an immunosuppressive state is effective and safe for the prevention of IFIs (Table 2).

Cost-effectiveness of posaconazole in the prevention of IFIs

Posaconazole is more effective in the prevention of IFIs than fluconazole or itraconazole (standard azoles) in immunocompromised patients, including patients with AML, MDS, and HSCT-GVHD; however, the economic burden of this preventive measure is important. Posaconazole prophylaxis is expected to be cost-effective compared with standardazole (fluconazole or itraconazole) prophylaxis. O’Sullivan et al investigated the cost-effectiveness of posaconazole oral suspension versus fluconazole or itraconazole in the prevention of IFIs among patients with AML or MDS and chemotherapy-induced neutropenia in the United States. They revealed that posaconazole was associated with
fewer IFIs per patient (0.05 versus 0.11) over 100 days of follow-up, lower discounted costs ($3,900 versus $4,500), and increased life-years (2.50 versus 2.43 discounted) over a lifetime compared with fluconazole and itraconazole. Additionally, they found that posaconazole was cost-saving versus fluconazole or itraconazole. Tahami Monfared et al evaluated the economic cost of posaconazole versus standard (fluconazole or itraconazole) prophylaxis against IFIs in patients with prolonged neutropenia in Canada. They found that posaconazole was associated with fewer cases of IFIs (0.05 versus 0.11; P=0.003), increased life-years (2.52 years versus 2.43 years), and slightly lower costs ($6,601 versus $7,045) per patient compared with standard azole therapy over a lifetime. Moreover, studies from European countries, including France, Italy, Switzerland, the Netherlands, Sweden, Greece, and Spain, demonstrated that posaconazole prophylaxis was more cost-effective and, in several studies, more cost-saving than standard azole prophylaxis in the prevention of IFIs in patients with AML, MDS, and HSCT-GVHD even with cancer. In addition to the clinical safety and efficacy trials, these economic analyses strongly suggest that posaconazole prophylaxis is superior to standard azole prophylaxis and more cost-effective and/or cost-saving in the prevention of IFIs in immunocompromised patients.

### Posaconazole (delayed-release tablet) prophylaxis for IFIs

No published clinical trials are available on the use of posaconazole delayed-release tablets in the prevention of IFIs in immunocompromised patients. However, Conant et al reported on a 65-year-old man with recurrent *Aspergillus* brain abscesses who was previously treated with surgical resection and voriconazole for 1 year, and who was subsequently treated with posaconazole delayed-release tablets with a maintenance dose of 300 mg per 24 hours, which resulted in a therapeutic serum concentration and was a safe and clinically effective treatment. This report was the first on the successful use of posaconazole tablets for the treatment of invasive aspergillosis. Before the accumulation of clinical data on the use of posaconazole delayed-release tablets in the prevention of IFIs in immunocompromised patients, an economic cost analysis of posaconazole tablets versus fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States was performed by Sung et al. They revealed that the average cost of antifungal prophylaxis was higher in the posaconazole tablet group compared with the fluconazole/itraconazole group ($4,673 versus $3,533). Additionally, they found that the costs that were associated with treating IFIs were lower in the posaconazole tablet group compared with the fluconazole/itraconazole group ($2,205 versus $5,303). The incremental cost-effectiveness ratio for IFIs that were prevented by posaconazole was $18,898 versus fluconazole/itraconazole. In the current health care environment, the authors concluded that posaconazole tablets are a cost-effective alternative to fluconazole or itraconazole in the prevention of IFIs among neutropenic patients with AML and MDS in the USA.

### Conclusion

The newly developed posaconazole delayed-release tablet formulation enables patients in an immunosuppressive state to receive concomitant medication and food, which negatively affect the bioavailability of posaconazole oral suspension. Oral posaconazole formulation is superior to standard azoles
(fluconazole or itraconazole) and more cost-effective in the prevention of IFIs in immunocompromised patients. To determine the clinical benefits of the posaconazole delayed-release tablet formulation either in the treatment or in the prevention of IFIs, well-designed clinical efficacy and safety studies are needed in both adult and pediatric populations.

Disclosure
The author reports no conflicts of interest in this work.

References

Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 54.70.40.11 on 21-Apr-2020


